¿Por qué el CÁNCER es tan RESISTENTE? | Heterogeneidad y resistencia

The transcript discusses the fundamental challenges in treating breast cancer, with heterogeneity being identified as one of medicine's biggest obstacles. The speaker explains that breast cancer varies not only between different patients, but even within individual tumors there exists great cellular diversity. This complexity is compounded by the existence of cancer stem cells (referred to as 'cancerous mother cells') that can survive current therapies and remain dormant for years before causing tumor recurrence. To address these challenges, Dr. María del Mar Vivanco leads a cancer heterogeneity laboratory focused on discovering biomarkers - molecular fingerprints that can identify patients at higher risk of tumor recurrence. The research has dual objectives: predicting relapses and finding molecules capable of preventing the recurrence process altogether. The team also investigates the intricate relationships between cancer stem cells, tumor cells, and their surrounding environment, as understanding these connections is crucial for identifying cancer stem cells. The speaker emphasizes that some tumors develop resistance to current therapies, making the search for more effective treatments essential.